Mocroft A, Lundgren J, Gerstoft J, et al. - Given an association of a hepatitis C (HCV) cure with changes in lipids and inflammatory biomarkers, researchers here examined its impact on clinical endpoints among treated human immunodeficiency virus (HIV)/HCV coinfected persons. Based on time-updated HCV RNA measurements and HCV treatment, following stratification of people living with HIV from EuroSIDA with a known HCV status after January 2001 was done: HCV antibody–negative; spontaneously resolved HCV; chronic, untreated HCV; cured HCV (HCV RNA–negative); or HCV treatment failures (HCV RNA–positive). Assessment of 16,618 persons was performed (median follow-up 8.3 years, interquartile range 3.1–13.7). Observations revealed no differences in incidences of non–acquired immunodeficiency virus defining malignancy (NADM; excluding HCC) or cardiovascular disease between the five HCV group. However, substantially lower incidences of end-stage liver disease (ESLD; including hepatocellular carcinoma [HCC]) were observed among cured cases. This highlights the importance of successful HCV treatment for reducing ESLD.